Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -60 | -17 | -7K | -7K | -7K |
| EBITDA | -68K | -18 | -7K | -7K | -7K |
| Net Income | -68 | -35 | -7K | -7K | -7K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+400.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solanbridge Group, Inc. (SLNX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 400.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow +38.7% with operating margin 0.0% and ROIC 78.7%. Stock Foundry combines SLNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLNX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLNX Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLNX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$7.3K
-8.6% YoY
Free Cash Flow
-$138.7K
-1955.6% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -60 | -17 | -7K | -7K | -7K |
| EBITDA | -68K | -18 | -7K | -7K | -7K |
| Net Income | -68 | -35 | -7K | -7K | -7K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 100 | 100 | 100 |
| Total Assets | 4 | 4 | 43K | 43K | 43K |
| Total Liabilities | 95 | 27 | 253K | 253K | 253K |
| Shareholder Equity | -91 | -23 | -243K | -236K | -230K |
| Total Debt | 15 | 8 | 253K | 253K | 253K |
| Net Debt | 15 | 8 | 253K | 253K | 253K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
139K
-1955.6% YoY
Capital Expenditures
0
Free Cash Flow
139K
-1955.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
118.2%
Debt / Equity
-0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.